Elevar Therapeutics

Fort Lee, New Jersey biopharmaceutical company and wholly owned U.S. subsidiary of HLB Co., Ltd. (South Korea) since 2019; in-licensed lirafugratinib from Relay Therapeutics in December 2024 and took it through to this approval.

elevartherapeutics.com

1 story

Regulatory News has published 1 story about Elevar Therapeutics on 30 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 30 September 2026.

This page is generated from Regulatory News’ editorial coverage of Elevar Therapeutics. It is not an advertisement.

Products in our coverage

Lyrfigtu™lirafugratinib

Our coverage

1 story, newest first.

A clinician in a white blouse reviews notes on a tablet in a bright office atrium

For Physicians FDA Approves Lyrfigtu, Third FGFR2 Drug for Bile Duct Cancer Sep 30, 202611 min read Read the story

All companies